COUP-1 (MZL-1) Copanlisib and Rituximab in Marginal Zone Lymphoma Patients (Aktiv)
Zweitlinie oder später
CC-220-NHL-001 A Phase 1/2, Multicenter, Open-Label Study to Assess Safety, Pharmacokinetics, and preliminary efficacy of CC-220, alone and in combination with an anti-CD20 Monoclonal Antibody (MAB) in subjects with relapsed or refractory Lymphomas (Aktiv)